The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Danilov D.S.

Klinika psikhiatrii im. S.S. Korsakova;
kafedra psikhiatrii i meditsinskoĭ psikhologii Moskovskoĭ meditsinskoĭ akademii im. I.M. Sechenova

Multimodal serotonergic antidepressants

Authors:

Danilov D.S.

More about the authors

Read: 13804 times


To cite this article:

Danilov DS. Multimodal serotonergic antidepressants. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(9):103‑111. (In Russ.)
https://doi.org/10.17116/jnevro201711791103-111

Recommended articles:
The Duchenne muscular dystrophy continuum: a modi­fied staging classification. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):60-70
Extramammary Paget’s disease. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(6):726-733
Classification of digi­tal medi­cal products and services. Medi­cal Technologies. Asse­ssment and Choice. 2026;(1):11-25

References:

  1. Agnoli A. History and pharmacology of trazodone (article in French). Encephale. 1986;12(Spec No):239-242.
  2. Trazodone: an Italian drug recently registered in the USSR (article in Italian). Minerva Medica. 1979;70(8):624-625.
  3. Dotevall G, Groll E. Controlled clinical trial of mepiprazole in irritable bowel syndrome. British Medical Journal. 1974;4(5935):16-18. https://doi.org/10.1136/bmj.4.5935.16
  4. Stefanini E, Fadda F, Medda L, Gessa GL. Selective inhibition of serotonin uptake by trazodone, a new antidepressant agent. Life Sciences. 1976;18(12):1459-1465. https://doi.org/10.1016/0024-3205(76)90364-7
  5. Valeri P, Angelucci L. Inhibition of monoamine uptake in brain by etoperidone (abstracts). 18th National Congress of the Italian Society of Pharmacology. 1st USSR — Italian Joint Meeting. Italy: Modena; 1976.
  6. Garattini S, De Gaetano G, Samanin R, Bernasconi S, Roncaglioni MC. Effects of trazodone on serotonin in the brain and platelets of the rat. Biochemical Pharmacology. 1976;25(1):13-16. https://doi.org/10.1016/0006-2952(76)90165-9
  7. 14C5-hydroxytryptamine uptake by rat platelets. Journal Pharmacy Pharmacology. 1977;29(9):546-549. https://doi.org/10.1111/j.2042-7158.1977.tb11393.x
  8. Riblet LA, Gatewood CF, Mayol RF. Comparative effects of trazodone and tricyclic antidepressants on uptake of selected neurotransmitters by isolated rat brain synaptosomes. Psychopharmacology (Berl). 1979;63(2):99-101. https://doi.org/10.1007/bf00429685
  9. Hingtgen JN, Hendrie HC, Aprison MH. Postsynaptic serotonergic blockade following chronic antidepressive treatment with trazodone in an animal model of depression. Pharmacology Biochemistry Behaviour. 1984;20(3):425-428. https://doi.org/10.1016/0091-3057(84)90281-8
  10. Riblet LA, Taylor DP. Pharmacology and neurochemistry of trazodone. Journal Clinical Psychopharmacology. 1981;1(6):17-22. https://doi.org/10.1097/00004714-198111001-00004
  11. Cohen ML, Fuller RW, Kurz KD. Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats. Hypertension. 1983;5(5):676-681. https://doi.org/10.1161/01.hyp.5.5.676
  12. Scott JA, Crews FT. Down-regulation of serotonin2, but not of beta-adrenergic receptors during chronic treatment with amitriptyline is independent of stimulation of serotonin2 and beta-adrenergic receptors. Neuropharmacology. 1986;25(12):1301-1306. https://doi.org/10.1016/0028-3908(86)90100-0
  13. Fuller RW, Snoddy HD, Cohen ML. Interactions of trazodone with serotonin neurons and receptors. Neuropharmacology. 1984;23(5):539-544. https://doi.org/10.1016/0028-3908(84)90027-3
  14. Maj J, Palider W, Rawłów А. Trazodone, a central serotonin antagonist and agonist. Journal Neural Transmission. 1979;44(3):237-248. https://doi.org/10.1007/bf01253065
  15. Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD. Nefazodone: preclinical pharmacology of a new antidepressant. Psychopharmacology Bulletin. 1990;26(3):311-315.
  16. Ikegami A, Maeda A, Hara H, Yamashita A, Sukamoto T, Ito K. Effect of trazodone (KB-831) and its metabolites on brain monoamines in rat (аrticle in Japanese). Nihon Yakurigaku Zasshi. 1989;93(3):145-154. https://doi.org/10.1254/fpj.93.145
  17. Rotzinger S, Bourin M, Akimoto Y, Coutts RT, Baker GB. Metabolism of some «second»- and «fourth»-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine. Cell Molecular Neurobiology. 1999;19(4):427-442.
  18. Cusack B, Nelson A, Richelson E. Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl). 1994;114(4):559-565. https://doi.org/10.1007/bf02244985
  19. Ashkenazi R, Finberg JP, Youdim MB. Effects of LM 5008, a selective inhibitor of 5-hydroxytryptamine uptake, on blood pressure and responses to sympathomimetic amines. British Journal Pharmacology. 1983;79(4):915-922. https://doi.org/10.1111/j.1476-5381.1983.tb10536.x
  20. Feighner JP, Pambakian R, Fowler RC, Boyer WF, D’Amico MF. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacology Bulletin. 1989;25(2):219-221.
  21. Kaul S, Shukla UA, Barbhaiya RH. Nonlinear pharmacokinetics of nefazodone after escalating single and multiple oral doses. Journal Clinical Pharmacology. 1995;35(8):830-839. https://doi.org/10.1002/j.1552-4604.1995.tb04127.x
  22. Ellingrod VL, Perry PJ. Nefazodone: a new antidepressant. American Journal Health-System Pharmacy. 1995;52(24):2799-2812.
  23. Marek GJ, McDougle CJ, Price LH, Seiden LS. A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl). 1992;109(1-2):2-11. https://doi.org/10.1007/bf02245475
  24. Walsh AE, Cowen PJ. Attenuation of the prolactin-stimulating and hyperthermic effects of nefazodone after subacute treatment. Journal Clinical Psychopharmacology. 1994;14(4):268-273. https://doi.org/10.1097/00004714-199408000-00007
  25. Jenck F, Moreau JL, Mutel V, Martin JR. Brain 5-HT1C receptors and antidepressants. Progress Neuropsychopharmacology Biological Psychiatry. 1994;18(3):563-574. https://doi.org/10.1016/0278-5846(94)90013-2
  26. Hemrick-Luecke SK, Snoddy HD, Fuller RW. Evaluation of nefazodone as a serotonin uptake inhibitor and a serotonin antagonist in vivo. Life Sciences. 1994;55(7):479-483. https://doi.org/10.1016/0024-3205(94)00739-x
  27. Pazzagli M, Giovannini MG, Pepeu G. Trazodone increases extracellular serotonin levels in the frontal cortex of rats. European Journal Pharmacology. 1999;383(3):249-257. https://doi.org/10.1016/s0014-2999(99)00644-5
  28. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. Journal Pharmacology Experimental Therapeutics. 1997;283(3):1305-1322.
  29. Artigas F, Perez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Archives General Psychiatry. 1994;51(3):248-251.
  30. Sharp T, Umbers V, Gartside SE. Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. British Journal Pharmacology. 1997;121(5):941-946. https://doi.org/10.1038/sj.bjp.0701235
  31. Dawson LA, Nguyen HQ. Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex. European Journal Pharmacology. 1998;345(1):41-46. https://doi.org/10.1016/s0014-2999(97)01580-x
  32. Conn PJ, Sanders-Bush E. Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. Journal Pharmacology Experimental Therapeutics. 1987;242(2):552-557.
  33. Li AA, Marek GJ, Hand TH, Seiden LS. Antidepressant-like effects of trazodone on a behavioral screen are mediated by trazodone, not the metabolite m-chlorophenylpiperazine. European Journal Pharmacology. 1990; 177(3):137-144. https://doi.org/10.1016/0014-2999(90)90263-6
  34. Raffa RB, Shank RP, Vaught JL. Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity. Psychopharmacology (Berl). 1992;108(3):320-326. https://doi.org/10.1007/bf02245118
  35. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacological Reviews. 1994;46(2):157-203.
  36. Chang T, Fava M. The future of psychopharmacology of depression. J Clin Psychiatry. 2010;71(8):971-975. https://doi.org/10.4088/jcp.10m06223blu
  37. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. Journal Affective Disorders. 1998;51(3):237-254. https://doi.org/10.1016/s0165-0327(98)00222-5
  38. Machado M, Iskedjian M, Ruiz I, Einarson TR. Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials. Current Medical Research Opinion. 2006;22(9):1825-1837. https://doi.org/10.1185/030079906x132415
  39. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M. STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurementbased care in STAR*D: implications for clinical practice. American Journal Psychiatry. 2006;163(1):28-240. https://doi.org/10.1176/appi.ajp.163.1.28
  40. Dawson LA. The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI? Expert Opinion Drug Discovery. 2013;8(12):1529-1539. https://doi.org/10.1517/17460441.2013.855195
  41. Cremers TI, Giorgetti M, Bosker FJ, Hogg S, Arnt J, Mørk A, Honig G, Bøgesø KP, Westerink BH, den Boer H, Wikstrom HV, Tecott LH. Inactivation of 5-HT(2C) receptors potentiates consequences of serotonin reuptake blockade. Neuropsychopharmacology. 2004;29(10):1782-1789. https://doi.org/10.1038/sj.npp.1300474
  42. Gartlehner G, Hansen RA, Thieda P, DeVeaugh-Geiss AM, Gaynes BN, Krebs EE, Lux LJ, Morgan LC, Shumate JA, Monroe LG, Lohr KN. Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression. Comparative Effectiveness Review No. 7. (Prepared by RTI International-University of North Carolina Evidence-based Practice Center under Contract No. 290-02-0016.) Rockville, MD: Agency for Healthcare Research and Quality. January 2007.
  43. 2-(2,4-dimethylphenylsulfanyl)phenylpiperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. Journal Medical Chemistry. 2011;54(9):3206-3221. https://doi.org/10.1021/jm101459g
  44. Stahl SM, Lee-Zimmerman C, Cartwright S, Morrissette DA. Serotonergic drugs for depression and beyond. Current Drug Targets. 2013;14(5):578-585. https://doi.org/10.2174/1389450111314050007
  45. Subhash MN, Srinivas BN, Vinod KY. Alterations in 5-HT(1A) receptors and adenylyl cyclase response by trazodone in regions of rat brain. Life Sciences. 2002;71(13):1559-1567. https://doi.org/10.1016/s0024-3205(02)01926-4
  46. 35SGTPgammaS binding. Journal Psychopharmacology. 2005;19(3): 235-241. https://doi.org/10.1177/0269881105051526
  47. Luparini MR, Garrone B, Pazzagli M, Pinza M, Pepeu G. A cortical GABA-5HT interaction in the mechanism of action of the antidepressant trazodone. Progress Neuro-Psychopharmacology Biological Psychiatry. 2004; 28(7):1117-1127. https://doi.org/10.1016/j.pnpbp.2004.05.046
  48. Alex KD, Pehek EA. Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacology Therapeutics. 2007;113(2): 296-320. https://doi.org/10.1016/j.pharmthera.2006.08.004
  49. Ghanbari R, El Mansari M, Blier P. Electrophysiological impact of trazodone on the dopamine and norepinephrine systems in the rat brain. European Neuropsychopharmacology. 2012;22(7):518-526. https://doi.org/10.1016/j.euroneuro.2011.11.005
  50. Millan MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005;60(5):441-460. https://doi.org/10.2515/therapie:2005065
  51. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectrums. 2009;14(10):536-546. https://doi.org/10.1017/s1092852900024020
  52. Ghanbari R, El Mansari M, Blier P. Sustained administration of trazodone enhances serotonergic neurotransmission: in vivo electrophysiological study in the rat brain. Journal Pharmacology Experimental Therapeutics. 2010;335(1):197-206. https://doi.org/10.1124/jpet.110.169417
  53. Frecska E. Trazodone — its multifunctional mechanism of action and clinical use (article in Hungarian). Neuropsychopharmacologia Hungarica. 2010;12(4):477-482.
  54. Fagiolini A, Comandini A, Catena Dell’Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26(12):1033-1049. https://doi.org/10.1007/s40263-012-0010-5
  55. DeVane CL, Grothe DR, Smith SL. Pharmacology of antidepressants: focus on nefazodone. Journal Clinical Psychiatry. 2002;63(suppl 1):10-17.
  56. Nutt DJ. Beyond psychoanaleptics — can we improve antidepressant drug nomenclature? Journal Psychopharmacology. 2009;23(4):343-345. https://doi.org/10.1177/0269881109105498
  57. Osváth P. Current treatment of depression and agitation in the elderly — clinical use of trazodone (аrticle in Hungarian). Neuropsychopharmacologia Hungarica. 2013;15(3):147-155.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.